Refine by
Cancer Screening Articles & Analysis
142 news found
Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. In dermatology, new methods for treating benign epidermal lesions are emerging, alongside the development of drug-free therapies to enhance patient well-being. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. SOPHiA GENETICS offers a ...
Globally, an estimated 19.3 million cancer cases occurred in 2020 alone, with a fatality rate of almost 10.0 million cancer deaths, with breast (11.7%), lung (11.4%), colorectal (10%) and prostate (7.3%) being the most fatal. ...
ByCELLINK
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
The company’s technology automates scoring of a patient’s minimum threshold score of disease severity, as measured by the Mayo Endoscopic Score (MES), as an aid in determining their qualification for pre-screening for IBD clinical trials. Iterative Scopes has already partnered with multiple clinical research sites for IBD and is continuing to expand its reach with ...
Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood-based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. We use advanced machine learning and computer vision ...
“As we continue to expand our clinical research program, we’re looking forward to improving our trial recruitment efforts with more accurate patient screening and identification, and ultimately, increasing patient access to trials and ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. We use advanced machine learning and computer vision ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading central European hospitals*, represented ...
Poster title: “Quantification of Beta-Hydroxybutyric acid and Tryptophan in plasma as metabolic biomarkers of cancer using the LDTD-MS/MS technique”. The poster attracted interest from many potential companies in the clinical lab space on the use of this novel integrated technology for cancer screening application. ...
“Pulmonary nodules are a big topic, particularly with the advent of chest CT in high-risk patients for the early detection of lung cancer,” Krestin states. There are many patients at risk who need these lung cancer screening exams, and radiologists are having to conduct them on a large scale. ...
ByFluidda
SKOUT, a real-time computer-aided polyp detection device with FDA 510(k) clearance, uses advanced computer vision technology designed to recognize suspicious tissue during colorectal cancer screening and surveillance. SKOUT significantly improves overall adenoma detection compared to standard colonoscopy. ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ...
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable ...
Lung cancer is the leading cause of cancer death accounting for almost one quarter of annual cancer deaths in the United States (US) and the rest of the world. The American Cancer Society estimates there will be ~236,000 new cases and ~130,000 deaths from lung cancer in the US in 2022. ...
InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in Health & Care Award. This partnership marks another significant step in the journey to build an evidence base to demonstrate the effectiveness and safety of artificial intelligence in NHS breast ...
Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technology designed to recognize suspicious tissue and provide real-time feedback to gastroenterologists. ...